Short Interest in Vicarious Surgical Inc. Soars 120% in January

Vicarious Surgical Inc. (NYSE:RBOT) experienced a dramatic increase in short interest in January 2024, with figures showing a rise of 120.1% compared to the previous month. As of January 15, short interest reached a total of 309,143 shares, up from 140,432 shares on December 31, 2023. This surge indicates a growing skepticism among investors, as approximately 5.2% of the company’s shares are currently sold short.

The short-interest ratio, calculated based on an average trading volume of 266,613 shares, stands at 1.2 days. This metric suggests that it would take just over a day to cover all short positions, reflecting a heightened level of trading activity surrounding Vicarious Surgical.

Stock Performance and Market Metrics

On January 12, shares of Vicarious Surgical closed at $2.21, gaining $0.13 during the trading session. The stock’s trading volume was 68,429 shares, which is notably lower than its average volume of 177,188 shares. Over the past 50 days, the stock has maintained a moving average of $2.50, while the 200-day moving average sits significantly higher at $5.15. The company currently boasts a market capitalization of $14.48 million and has a price-to-earnings ratio of -0.24.

In terms of price fluctuations, Vicarious Surgical has seen a 12-month low of $1.80 and a high of $16.35, indicating considerable volatility in its stock performance.

Recent Earnings and Analyst Insights

Vicarious Surgical released its quarterly earnings report on November 12, 2023, revealing an earnings per share (EPS) of ($1.91). This figure surpassed analysts’ expectations, which had been set at ($2.37), providing a positive surprise of $0.46. Looking ahead, analysts predict a projected EPS of ($10.89) for the current fiscal year.

The stock has drawn attention from several analysts in recent weeks. On December 12, 2023, BTIG Research reaffirmed a “neutral” rating on Vicarious Surgical shares. In contrast, Weiss Ratings assigned a “sell (e+)” rating in a note dated January 21, 2024. Additionally, Wall Street Zen downgraded the stock from a “hold” to a “sell” rating. Currently, two research analysts have issued a hold rating, while one has marked the stock as a sell. According to data from MarketBeat.com, Vicarious Surgical has a consensus rating of “Reduce” and a price target of $7.00.

In summary, the significant rise in short interest reflects a critical moment for Vicarious Surgical as it navigates market challenges and investor sentiment. As the company continues to develop its innovative robotic surgical technology, stakeholders are keenly watching how these dynamics will unfold in the coming months.